Compare Enbridge Inc (ENB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enbridge Inc trades at $51.53 (market cap $112.62B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Enbridge Inc pays a 5.34% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Enbridge Inc nearer its low. Which is the better fit depends on your goals.
| ENB | XBI | |
|---|---|---|
Market Cap | $112.62B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.04 | $164.28 |
52-Week Low | $45.23 | $86.92 |
Enterprise Value | $196.53B | — |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.49, up 0.19% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company reported Q2 2026 EPS of $0.46, beating estimates of $0.43, and maintains a strong dividend yield with 31 consecutive years of increases. Revenue for 2025 reached $65.19B, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is stable with growth supported by a $41B project backlog and utility demand, but risks include regulatory challenges like pipeline disputes and high debt levels. The stock offers income appeal through dividends, yet faces headwinds from energy market volatility and legal uncertainties.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
